Chronic Kidney Disease & Electrolytes • ICD-10-CM N17.0
Tubular necrosis - acute
Also known as: Infarction, Stroke, Bleed, Necrosis
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM N17.0 • 4 Linked .gov / PubMed Citations
•
Governance: Dr. Julian Sterling, MD, FACS (NPI #1376841536)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Tubular necrosis - acute Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Chronic Kidney Disease & Electrolytes diagnostic criteria (N17.0), workup for Tubular necrosis - acute (also termed Infarction or Stroke) integrates NSAID/nephrotoxin avoidance [Tubular necrosis - acute N17.0] with evidence-graded therapy tailored to Urine Albumin-to-Creatinine Ratio in Tubular necrosis - acute (N17.0: (uACR)) response.
- 2 Real-world patient consensus: Synonyms for Tubular necrosis - acute (N17.0): Infarction, Stroke, Bleed (Kidney & Renal).
- 3 Typical cash cost range: Workup highlights for Tubular necrosis - acute (N17.0): NSAID/nephrotoxin avoidance [Tubular necrosis - acute N17.0].
- 4 Top reported side effects / signs: Follow-up benchmark in Tubular necrosis - acute: maintaining Urine Albumin-to-Creatinine Ratio in Tubular necrosis - acute (N17.0: (uACR)) within < 15 mg/g (< 30 mg/g normal) (N17.0).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Tubular necrosis - acute
What Is Tubular necrosis - acute?
Under Chronic Kidney Disease & Electrolytes diagnostic criteria (N17.0), workup for Tubular necrosis - acute (also termed Infarction or Stroke) integrates NSAID/nephrotoxin avoidance [Tubular necrosis - acute N17.0] with evidence-graded therapy tailored to Urine Albumin-to-Creatinine Ratio in Tubular necrosis - acute (N17.0: (uACR)) response.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Tubular necrosis - acute (code N17.0) is tubulointerstitial fibrosis [Tubular necrosis - acute N17.0], which Chronic Kidney Disease & Electrolytes clinicians address while surveilling Urine Albumin-to-Creatinine Ratio in Tubular necrosis - acute (N17.0: (uACR)) (< 15 mg/g (< 30 mg/g normal) (N17.0)).
Common Symptoms & Clinical Signs
- • Presentation of Tubular necrosis - acute (N17.0): asymptomatic decline in in Tubular necrosis - acute (N17.0: eGFR or persistent)
- • Secondary Tubular necrosis - acute clinical sign: fluid retention in in Tubular necrosis - acute (N17.0: ankles, hands, or)
- • Symptom flares in Tubular necrosis - acute correlating with Urine Albumin-to-Creatinine Ratio in Tubular necrosis - acute (N17.0: (uACR)) deviation outside < 15 mg/g (< 30 mg/g normal) (N17.0)
- • Functional kidney & renal impact requiring NSAID/nephrotoxin avoidance [Tubular necrosis - acute N17.0] evaluation (N17.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Tubular necrosis - acute Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | N17.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Chronic Kidney Disease & Electrolytes | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio in Tubular necrosis - acute (N17.0: (uACR)) | < 15 mg/g (< 30 mg/g normal) (N17.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Potassium, Bicarbonate in Tubular necrosis - acute (N17.0: & Phosphorus) | K+ 3.8–4.8 mEq/L; HCO3 23–29 mEq/L (N17.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: eGFR (Creatinine + in Tubular necrosis - acute (N17.0: Cystatin C)) | >= 90 mL/min/1.73m2 (N17.0) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Tubular necrosis - acute
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Etanercept Enbrel • RxCUI RXN-58406032-2382 | Tumor Necrosis Factor Blocker | 86% | $1984.1427 | $ 185.00 /mo |
| Certolizumab Pegol Cimzia • RxCUI 795081 | Tumor Necrosis Factor Blocker | 77% | $5783.3464 | $ 185.00 /mo |
| Yusimry (Adalimumab-Aqvh) Yusimry • RxCUI 2640395 | Tumor Necrosis Factor Blocker | 81% | $604.1525 | $ 526.75 /mo |
| Adalimumab-Adaz Hyrimoz • RxCUI RXN-83457102-2276 | Tumor Necrosis Factor Blocker | 83% | $1586.7323 | $ 185.00 /mo |
| Amjevita (Adalimumab-Atto) Amjevita • RxCUI 2627711 | Tumor Necrosis Factor Blocker | 92% | $872.7719 | $ 640.00 /mo |
| Infliximab-Axxq Avsola • RxCUI RXN-55513670-3213 | Tumor Necrosis Factor Blocker | 75% | $1.2300 | $ 58.32 /mo |
| Simponi Aria (Golimumab) Simponi Aria • RxCUI 1431647 | Tumor Necrosis Factor Blocker | 90% | $2.4900 | $ 187.78 /mo |
| Hadlima (Adalimumab-Bwwd) Hadlima • RxCUI RXN-B500906707 | Tumor Necrosis Factor Blocker | 82% | $1254.6130 | $ 640.00 /mo |
| Cimzia (Certolizumab Pegol) Cimzia • RxCUI 795085 | Tumor Necrosis Factor Blocker | 93% | $5783.3464 | $ 640.00 /mo |
| Golimumab Simponi Aria, Simponi • RxCUI 1431642 | Tumor Necrosis Factor Blocker | 89% | $12356.6836 | $ 185.00 /mo |
| Zymfentra (Infliximab-Dyyb) Zymfentra • RxCUI RXN-B72606025 | Tumor Necrosis Factor Blocker | 82% | $2.9600 | $ 221.62 /mo |
| Adalimumab-Aqvh Yusimry • RxCUI 2640389 | Tumor Necrosis Factor Blocker | 88% | $604.1525 | $ 185.00 /mo |
| Infliximab Renflexis, Remicade • RxCUI 1927285 | Tumor Necrosis Factor Blocker | 74% | $1135.9660 | $ 185.00 /mo |
| Adalimumab-Bwwd Hadlima • RxCUI RXN-83457186-2277 | Tumor Necrosis Factor Blocker | 92% | $1254.6130 | $ 185.00 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Tubular necrosis - acute)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Proximal tubular dysfunction in pregnant women receiving tenofovir disoproxil: What a 291-Participant Study Found In these HBV-infected pregnant and breastfeeding women, tenofovir disoproxil fumarate administered from 28-wk-GA to 2-months-PP was not associated with a higher risk of proximal tubulopathy. The Journal of antimicrobial chemotherapy • 2022-03-31 • Phase III Randomized Trial | N = 291 | 93/100 | PMID 35045168 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Tubular necrosis - acute Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Tubular necrosis - acute community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Tubular necrosis - acute.